RT Journal Article
SR Electronic
T1 Moving Beyond Clinical Risk Scores with a Mobile App for the Genomic Risk of Coronary Artery Disease
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 101519
DO 10.1101/101519
A1 Evan D. Muse
A1 Nathan E. Wineinger
A1 Brian Schrader
A1 Bhuvan Molparia
A1 Emily G. Spencer
A1 Dale L. Bodian
A1 Ali Torkamani
A1 Eric J. Topol
YR 2017
UL http://biorxiv.org/content/early/2017/01/19/101519.abstract
AB Primary prevention of coronary artery disease (CAD) is important for individuals at increased risk, and largely consists of healthy lifestyle modifications and initiation of medications when appropriate – including statins. Defining the inherent risk for any given individual typically relies on traditional risk factors established decades ago by the Framingham Heart Study. Unfortunately, recent studies have indicated that these traditional clinical risk factors systematically overestimate the risk of CAD across all major ancestries. This has increased the number of patients that would be eligible for statin therapy for the primary prevention of CAD but would likely receive little benefit and potentially incur negative consequences. On the other hand, researchers have demonstrated that genetic factors can effectively identify a subset of high risk individuals, and that the benefit from statin therapy is greatest among individuals with the highest genetic risk score (GRS). These individuals also receive the greatest absolute benefit from healthy lifestyle choices, being able to titrate their risk to normal levels despite high genetic predisposition. However, it is not yet possible for the average individual to discover their genetic risk because no tools are currently available to make such a determination. Here, we present a free mobile app – MyGeneRank – that can provide this information. Individuals may choose to use this knowledge to complement traditional risk assessments, and make critical decisions regarding lifelong statin therapy and lifestyle changes. As of 1/25/2017, MyGeneRank is currently in closed beta and will soon be available to the public.